Research Paper Volume 13, Issue 14 pp 18701—18717
Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma
Figure 7. Validation of the epigenetic-based prognostic risk signature in the GSE31210 cohort. (A) The risk score distribution of LUAD patients. (B) Survival status and duration of patients. (C) Heatmap of the epigenetic-related genes expression. (D) Survival curves for the low risk and high risk groups. (E) Time-independent receiver operating characteristic (ROC) analysis of risk scores for predicting the overall survival in the GSE31210 set.